Clinical Trial Update: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma [Phase 2]

View source ↗

Summary

An open-label Phase 2 pilot trial evaluates lenalidomide (Revlimid) as adjuvant therapy for refractory Cutaneous T Cell Lymphoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: Florida Academic Dermatology Centers | Conditions: Cutaneous T Cell Lymphoma | Phase 2 | Status: UNKNOWN